Global Intellectual Property Specialists

Strategic global thinking for the pharmaceutical and biopharmaceutical industries

Our Capabilities

We use our global experience to support life sciences clients from early R&D to commercial launch, and beyond.

Explore our BioBlast®

View our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date.

Our People

Our lawyers and attorneys have science backgrounds, were trained at top tier firms, and most have experience in-house at multinational giants.

Award-winning IP services

Ranked internationally and domestically, our pharmaceutical, biopharmaceutical and life sciences focussed lawyers and attorneys are recognised as being among the best IP practitioners in the world.

PEARCE IP

Our Capabilities

Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.

We coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.

Patent: Legal and Attorney Services

Trade Mark: Legal and Attorney Services

Commercial IP Services

Regulatory Affairs Services

View our Capabilities

IP SPECIALISTS LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS

Our Leaders

Naomi Pearce

Executive Lawyer, Patent Attorney & Trade Mark Attorney

CEO

Katrina Crooks

Executive Lawyer and Patent Attorney

Head of Litigation

Jacinta Flattery O’Brien PhD

Special Counsel, Patent Attorney

Jennifer Enmon PhD, JD

Special Counsel, Patent Attorney, Trade Mark Attorney

Head of Prosecution

Grant Shoebridge PhD

Special Counsel, Patent Attorney

Kate Legge

Special Counsel, Lawyer

PEARCE IP BLOG

Read our latest updates & insights

Medicinal Cannabis in Australia | Part 5: Making therapeutic claims: advertising and labelling of medicinal cannabis products

Medicinal Cannabis in Australia | Part 5: Making therapeutic claims: advertising and labelling of medicinal cannabis products

Medicinal Cannabis in Australia | Part 5: Making therapeutic claims: advertising and labelling of medicinal cannabis products

by Kate Legge, Katrina Crooks | May 17, 2022

Introduction The promotion of medicinal cannabis products presents some specific challenges given that very few such...

Pearce IP BioBlast®: w/e 13 May 2022

Pearce IP BioBlast®: w/e 13 May 2022

Pearce IP BioBlast®: w/e 13 May 2022

by Naomi Pearce, Emily Bristow | May 17, 2022

04 May 22 | Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal...

Read all News Stories

Explore our BioBlast®

Product specific reports based on extracts from our BioBlast® database

adalimumab | Humira® | AbbVie

aflibercept | Eylea® | Regeneron

bevacizumab | Avastin® | Roche/Genentech

cetuximab | Erbitux® | BMS/Merck

darbepoetin | Aranesp® | Amgen

denosumab | Prolia®/Xgeva® | Amgen

eculizumab | Soliris® | Alexion

etanercept | Enbrel® | Amgen

filgrastim (GCSF) | Neupogen® | Amgen

golimumab | Simponi® | Janssen

infliximab | Remicade® | Johnson & Johnson

natalizumab | Tysabri® | Biogen/Elan

omalizumab | Xolair® | Genentech / Novartis

pegfilgrastim | Neulasta® | Amgen

pembrolizumab | Keytruda® | Merck

pertuzumab | Perjeta® | Roche

ranibizumab | Lucentis® | Genentech

rituximab | Rituxan®/MabThera® | Genentech/Biogen

tocilizumab | Actemra® | Roche

trastuzumab | Herceptin® | Roche/Genentech

ustekinumab | Stelara® | Johnson & Johnson

View latest BioBlast® updates

See all Bioblast Updates

OUR VISION

By 2027, be the premier life sciences IP practice in Australia.

Contact Our Team

AWARD WINNING IP SPECIALISTS LAWYERS - PATENT ATTORNEYS - TRADE MARK ATTORNEYS

Awards